Item 2.02. Results of Operations and Financial Condition.

On February 10, 2023, Integrated Biopharma, Inc. (the "Company") issued a press release announcing its financial results for the three months ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 2.02.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:




99.1     Press Release dated February 10, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)































                                      -1-

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses